A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-parallel, multicenter phase 3 clinical trial to evaluate the efficacy of TG103 injection 7.5mg and 15mg once a week monotherapy compared with placebo in subjects with type 2 diabetes with poor glycemic control after diet and exercise.